Hospira pharmaceutical acquisition

0

Hospira, Inc., and Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, today announced

that the Hart-Scott-Rodino (HSR) review period for Hospira’s proposed acquisition of Orchid’s generic injectable pharmaceuticals business has expired with no action by the Federal Trade Commission (FTC).

The expiration of the HSR review period satisfies one of the conditions necessary for the transaction to close. Hospira and Orchid expect that, subject to the remaining customary closing conditions, the transaction will be completed in March.

Click here for the full press release.

Share.

Comments are closed.

Free Email Updates
Join 5.5K IVTEAM members. Subscribe now and be the first to receive all the latest free updates from IVTEAM!
100% Privacy. We don't spam.